Scios merger talks
Executive Summary
Scios is in discussions with a "number of life sciences companies concerning potential strategic transactions," the company said in response to reports it is in merger talks with Johnson & Johnson. The transactions under discussion include a merger deal and partnership for Scios' rheumatoid arthritis oral p38 MAP kinase inhibitor program (Phase II SCIO-469 and Phase I SCIO-323). Scios has been previously touted as an acquisition target, given the success of the congestive heart failure drug Natrecor. J&J's recent acquisitions include Alza (2001) and Centocor (1999)...
You may also be interested in...
J&J Buys Scios: Will Natrecor Make Another Centocor?
Johnson & Johnson will gain access to Scios' Phase II oral rheumatoid arthritis program through its proposed $2.4 bil. acquisition of the biotech company
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.